Group 1: Financial Performance - In 2024, the company achieved operating revenue of 336.80 million yuan, a year-on-year increase of 48.11% [1] - The net profit attributable to shareholders reached 11.45 million yuan, up 313.82% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 3.30 million yuan, reflecting a year-on-year increase of 120.29% [1] Group 2: Business Development Plans for 2025 - The company will focus on network security as its core, expanding into comprehensive information solutions [2] - In network security, the company aims to develop various product forms based on market demand, enhancing the usage scenarios of its security platform products [2] - The company plans to advance the development of specialized chips based on network security coding applications, completing two projects: SIP100 and SIP400 [2] Group 3: Medical Data and AI Integration - The company has completed several systems for electronic medical records and will continue to develop medical data projects in 2025 [3] - The focus will be on integrating AI into medical applications, enhancing efficiency and accuracy in daily medical tasks [3] - The company aims to establish a local AI model training environment to improve diagnostic accuracy while ensuring data privacy through federated learning [3] Group 4: Product Introduction and Market Strategy - The company introduced the "Electronic Medical Record Quality Control Intelligent Integration Machine," addressing core pain points in hospitals [4] - This product utilizes AI to enhance the depth and efficiency of medical record quality control, significantly improving quality control efficiency compared to manual methods [4] - The market expansion for this product is on track, with expectations to generate orders within the year [4]

Core Viewpoint - The company, Jiayuan Technology, has shown significant growth in revenue and net profit for 2024, indicating strong performance and future potential in the network security and information technology sectors [2][5]. Financial Performance - For 2024, the company achieved a revenue of 336.80 million yuan, representing a year-on-year increase of 48.11% [2][5]. - The net profit attributable to shareholders was 11.45 million yuan, up 313.82% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was 3.30 million yuan, an increase of 120.29% year-on-year [2]. Business Strategy and Future Growth - The company plans to align its operations with the national "14th Five-Year Plan," focusing on network security in specialized industries and expanding its comprehensive information solutions business [2][4]. - Key drivers for future growth include enhancing research and production capabilities, strengthening the sales system, and transitioning from customized products to standardized products [5]. - The company aims to capture opportunities in the medical information technology market, enhancing its core competitiveness and increasing market share [4]. Industry Outlook - The network security sector is expected to grow rapidly due to its elevation to a national strategic priority, supported by relevant laws and policies [4]. - The medical information technology market in China is projected to expand, with significant opportunities in areas such as hospital information system upgrades and regional medical collaboration [4].

证券代码：301117 证券简称：佳缘科技 公告编号：2025-039 佳缘科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 佳缘科技股份有限公司（以下简称"公司"）2024 年年度权益分派方案已获 2025 年 5 月 15 日召开的 2024 年年度股东大会审议通过，现将权益分派事宜公 告如下： 一、股东大会审议通过权益分派方案情况 1、公司于 2025 年 5 月 15 日召开 2024 年年度股东大会审议通过的 2024 年 度利润分配方案为：以公司 2024 年 12 月 31 日的总股本 92,263,300 股为基数， 向全体股东每 10 股派发现金红利 0.2 元（含税），以资本公积金转增股本每 10 股转增 4 股。预计派发现金股利人民币 1,845,266 元，转增后公司总股本增至 129,168,620 股（具体数量以中国证券登记结算有限责任公司深圳分公司登记结 果为准）。若在利润分配方案公告后至实施前，出现股权激励行权、可转债转股、 股份回购等股本总额发生变动情形时，将按照"现金分红总额 ...

Financial Performance - The company achieved operating revenue of 336.80 million yuan, a year-on-year increase of 48.11% [2] - Net profit attributable to shareholders reached 11.45 million yuan, up 313.82% year-on-year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.30 million yuan, reflecting a year-on-year increase of 120.29% [2] Future Growth Drivers - The company will align its operations with the national "14th Five-Year" strategic plan, focusing on cybersecurity and expanding integrated information solutions [2] - Continuous enhancement of research and production capabilities, along with strengthening the sales system to improve cash collection [2] - Emphasis on internal control systems to ensure compliance and exploring innovative business models to transition from customized to standardized products [2] Industry Outlook - The cybersecurity sector is increasingly recognized as a national strategic priority, supported by relevant laws and policies that foster rapid industry growth [3] - The medical informationization market in China is expected to grow, with opportunities in regional medical information systems and AI applications [3] - The company aims to enhance its core competitiveness and expand its market share in the medical informationization sector [3] Business Expansion Plans - In 2025, the company will focus on cybersecurity and integrated information solutions, while actively developing medical AI products targeted at hospitals [3] - The company is confident in achieving its performance targets set at the beginning of the year [3]

中信证券股份有限公司 关于佳缘科技股份有限公司 2024年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：佳缘科技 | | --- | --- | | 保荐代表人姓名：马峥 | 联系电话：010-60833052 | | 保荐代表人姓名：郑绪鑫 | 联系电话：021-20262370 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据《佳缘科技股份有限公司2024年度内 部控制自我评价报告》、《佳缘科技股份有限 | | | 公司2024年度内部控制审计报告（信会师报字 | | | [2025]第ZA90437号）》，发行人有效执行 ...

证券代码：301117 证券简称：佳缘科技 公告编号：2025-038 佳缘科技股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次会议不存在否决议案的情形； 2、本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召集人：佳缘科技股份有限公司（以下简称"公司"）董事会 2、会议主持人：副董事长、总经理朱伟民先生 3、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开的日期、时间： 现场会议召开日期、时间为：2025年5月15日（星期四）14:50 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年5月15日 的交易时间，即9:15-9:25 ，9:30-11:30和13:00-15:00。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为：2025年5 月15日9:15-15:00。 5、本次股东大会召开方式：本次股东大会采取现场投票、网络投票相结合 ...

北京德恒（深圳）律师事务所 关于佳缘科技股份有限公司 2024 年年度股东大会的 法律意见 深圳市福田区金田路 4018 号安联大厦 B 座 11 楼 电话:0755-88286488 传真:0755-88286499 邮编:518038 关于佳缘科技股份有限公司 北京德恒（深圳）律师事务所 2024 年年度股东大会的法律意见 北京德恒（深圳）律师事务所 关于佳缘科技股份有限公司 2024 年年度股东大会的 法律意见 德恒 06G20240260-0005 号 致：佳缘科技股份有限公司 佳缘科技股份有限公司（以下简称"公司"）2024 年年度股东大会（以下 简称"本次会议"）于 2025 年 5 月 15 日召开。北京德恒（深圳）律师事务所（以 下简称"德恒"）受公司委托，指派罗元清律师、林培伟律师（以下简称"德恒 律师"）出席了本次会议。根据《中华人民共和国证券法》（以下简称"《证券 法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公 司股东会规则》（以下简称"《股东会规则》"）、《佳缘科技股份有限公司章 程》（以下简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开 程序、现场 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

证券代码：301117 证券简称：佳缘科技 公告编号：2025-037 佳缘科技股份有限公司 关于举行 2024 年度网上业绩说明会的公告 佳缘科技股份有限公司（以下简称"公司"）2021 年年度报告及其摘要已于 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 佳缘科技股份有限公司（以下简称"公司"）《2024 年年度报告》已于 2025 年 4 月 24 日在巨潮资讯网（www.cninfo.com.cn）披露，为了让投资者能进一步 了解公司 2024 年度经营情况，公司拟定于 2025 年 5 月 20 日（星期二）15:00- 17:00 举行 2024 年度业绩说明会，现将有关事项公告如下： 二、公司参与人员 公司出席本次业绩说明会的人员有：副董事长兼总经理朱伟民先生、独立董 事赵宇虹先生、副总经理兼财务总监柳絮女士、副总经理兼董事会秘书张顺先生、 保荐代表人马峥先生（如遇特殊情况，参会人员可能进行调整）。 三、投资者问题征集方式 为充分尊重投资者、提升交流的针对性，公司现提前向投资者征集相关问题， 广泛听取投资者的意见和建议。投资者可提前登录深交所" ...

证券代码：301117 证券简称：佳缘科技 公告编号：2025-036 佳缘科技股份有限公司 关于特定股东减持计划实施进展暨减持完毕的公告 注：本公告中的比例保留 4 位小数，若出现总数与各分项数值之和尾数不符 的情况，为四舍五入原因造成。 二、其他相关说明 厦门鑫瑞集英创业投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 佳缘科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 3 月 14 日在巨潮资讯网披露了《关于特定股东减持股份预披露的公告》，持有公司股 份 1,800,000 股（占本公司总股本比例 1.95%）的股东厦门鑫瑞集英创业投资合 伙企业（有限合伙）（以下简称"鑫瑞集英"）计划在公告之日起 15 个交易日 后的 3 个月内以大宗交易方式和/或集中竞价交易方式合计减持本公司股份不超 过 1,800,000 股（占本公司总股本比例 1.95%）。 近日，公司收到鑫瑞集英出具的《关于股份减持计划实施完毕的告知函》， 截至告知函出具之日鑫瑞集英的减持计划已实施完 ...